We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,700+

Open access books available

180,000+

International authors and editors

195M+ Downloads

156

Countries delivered to

Our authors are among the

Top 1% most cited scientists

12.2%

Contributors from top 500 universities

Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

### Interested in publishing with us? Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected. For more information visit www.intechopen.com

## Meet the editor

Dr. Ahmed Lasfar is a faculty member at Rutgers University and a full member of the Rutgers Cancer Institute of New Jersey, USA. He is an editor and board member of several international journals and books. Dr. Lasfar is a scientific adviser and consultant to the pharmaceutical industry and a member of several medical and scientific societies. He graduated in Medical and Applied Science (BS/MD) and obtained a Ph.D. in Immunology from

Paris Diderot University, France. Dr. Lasfar completed his postdoctoral training in cancer immunology at Robert Wood Johnson Medical School, New Jersey, USA.

### Contents



Preface

The tumor microenvironment (TME) is a crucial aspect of all cancer types. It is well established now that TME plays an important role in both the control and the development of solid tumors. The histology of TME consists of a variety of normal resident and recruited cells, which are involved in concise and dynamic interactions with cancer cells. These interactions, which occur via released factors or cell-to-cell contact, are fundamental in tumor-induced suppression and metastatic dissemination of cancer cells, ultimately leading to morbidity and/or mortality for most cancer patients. Considerable progress has been made in understanding the mechanisms by which the TME contributes to the inhibition or promotion of cancer, enabling the emergence of a range of novel targeted therapies. In addition to stroma-targeted strategies, checkpoint inhibitor-based immunotherapy has emerged as a new treatment of choice for many advanced cancers. However, many cancer patients remain resistant to current therapies, necessitating the development of more innovative therapeutic strategies based on the identification of new targets and combining drugs that could counteract resistance. In this book, *Tumor Microenvironment – New Insights*, the authors highlight this aspect with chapters that describe and discuss innovative and impactful studies.

Prominent efforts and collaborations with leading experts in cancer were crucial in achieving this highly valuable book. We thank all the authors for their tremendous expertise and their exceptional quality in pointing out the crucial role of TME in cancer. Understanding and targeting TME constitutes a new hope for cancer patients,

**Ahmed Lasfar**

NJ, USA

Rutgers University,

Department of Toxicology and Pharmacology,

particularly those with advanced diseases.
